Morepen Laboratories Ltd

- Morepen Laboratories recently completed a significant equity fundraising round, raising approximately ₹565 crores through promoter subscriptions and external investors like Corinth investing $32.5 million directly into Morepen (Pages 14-15). - The total targeted fundraise is around ₹750 crores, with 75% going to Morepen (Page 14). - The company plans to utilize these funds primarily for four projects including API expansion, diagnostic devices, and formulation (Page 15). - No plans currently to raise debt; the company is debt-free except for preference capital which is to be redeemed (Page 12). - Expansion and CAPEX are funded through internal accruals and equity infusion, avoiding additional banking debt (Pages 8, 12). - CAPEX worth ₹178 crores for the new API block is being completed in phases over the next 2-3 years (Page 13).

- Morepen Laboratories has a significant expansion plan with a total investment of around Rs. 178 crores for a new API production block, expected to be commercialized over 3 years in phases. - An additional Rs. 55 crores is allocated to setting up a new R&D center focused on new molecules for APIs and Finished Dosage formulations. - Plans include expanding diagnostic devices and Finished Dosage segments: - Diagnostic devices business is growing exponentially and will be spun off as a separate subsidiary. - Finished Dosage expansion with a Rs. 100 crore CAPEX for automatic packaging and machining lines, targeting diabetic and cardiac product markets, expected over 2 years. - Total investment funding combines internal accruals, promoter equity infusion (Rs. 300 crores), and external investor funding (e.g., Rs. 32.5 million from Corinth). - New projects, including API expansion and diagnostic device development, have approvals in place; land acquisition underway.

- Morepen Laboratories aims to sustain and continue its growth trajectory across all business segments. - The company targets a revenue run rate of around ₹1200 crores annually, with quarterly averages around ₹300 crores. - Device business expects exponential growth in next 3 years, targeting ₹2000 crores production value in 3-5 years. - Capex plans of ₹150 crores and ₹100 crores for expansion in API and Finished Dosage segments respectively, over 2-3 years. - Plans to grow diagnostic devices from current 5 million meters installed, targeting broader market penetration, including tier 3/4 cities. - ANDAs filing and R&D focus anticipate new product launches in diabetics and cardiac markets by 2025-26. - Increased online presence with plans to expand from 100 to 500 (health and wellness) products in 3 years. - Regulatory approvals and environmental clearances support expansion projects aiming for full commercial production in 3 years. - COVID-related demand may normalize, but overall lifestyle changes signal sustained growth in diagnostics.

- Management is confident of continuing the growth trajectory, supported by sustainability and a well-geared team (Page 17). - Currently, EBITDA margin is around 11%, below typical pharma range of 18-20%, indicating room for margin improvement as exports and forward integration into Finished Dosages increase (Page 17). - Long-term plans include ramping up API, Diagnostic Devices, Finished Dosage, and OTC segments, with significant CAPEX and R&D investments to support growth (Pages 16, 8). - Expansion projects expected to raise production capacity and product pipeline; aiming for revenue values of Rs. 2000-4000 crores over next 3-5 years from devices and formulations (Pages 10, 8). - EPS rose 189% last year to Rs. 2.16 per share, indicating strong profit growth, with management optimistic about sustaining upward trends despite pandemic-related market fluctuations (Pages 10, 17). - Equity infusion of approx Rs. 565 crores planned to fund expansion, signaling commitment to scaling operations and profitability (Page 15).

The provided transcript from Morepen Laboratories Limited does not explicitly mention details about the current or expected order book or pending orders. However, some relevant points related to business growth and capacity expansion include: - The company is gearing up for major growth with multiple business segments: API, Diagnostic Devices, Finished Dosage, and OTC. - They have an ongoing CAPEX plan, including a ₹178 crore API expansion project and a ₹100 crore Finished Dosage project expected to complete by 2025-26. - Export business is strong, contributing about 39% of total revenue, with API exports growing 44% and diagnostic devices by 71%. - The company highlights new customer additions (103 customers) and expanding to over 80 countries. - Expected product pipeline includes 13 ANDAs nearing various stages of development and significant R&D investments. - The company is confident of a continued growth trajectory fueled by expansion and market opportunities. No explicit order book or pending order value was disclosed.